What is the optimal radiotherapy regimen for a segment‑6 liver lesion involving the portal‑venous branch?

Radiotherapy Regimen for Segment-6 Liver Lesion with Portal Vein Involvement

For a segment-6 HCC lesion with portal vein tumor thrombus (PVTT), stereotactic body radiation therapy (SBRT) delivering 30-50 Gy in 3-5 fractions (targeting BED >75 Gy₁₀) is the optimal radiotherapy approach, ideally combined with transarterial chemoembolization (TACE) within one month post-RT and systemic therapy with TKI plus immunotherapy. 1, 2, 3

Treatment Framework

Primary Radiotherapy Approach

SBRT is the preferred radiation modality for this clinical scenario based on current guidelines 4, 1. The technical specifications are:

• Dose range: 30-50 Gy in 3-5 fractions 1
• Target BED: >75 Gy₁₀ (critical threshold for improved outcomes) 3
• Alternative hypofractionated regimen: 50-60 Gy in 10 fractions (BED 56-75 Gy₁₀) 5

The most recent high-quality evidence from 2025 using MRI-guided radiotherapy demonstrated a 77.7% one-year local control rate with median overall survival of 10.6 months using hypofractionated RT 2. Importantly, dose escalation above 75 Gy₁₀ BED significantly improves outcomes: patients receiving >75 Gy₁₀ achieved 93.3% vs 45.6% local control at one year and median survival of 24.7 months vs 6.1 months compared to lower doses 3.

Critical Eligibility Considerations

Before proceeding with SBRT, verify:

• Liver function: Child-Pugh Class A is ideal; Class B requires dose modifications and strict constraint adherence 1
• Sufficient uninvolved liver: Must meet normal liver dose constraints 1
• Performance status: ECOG 0-2 6
• No Child-Pugh Class C: Safety not established in this population 1

Important caveat: While guidelines state macroscopic portal vein invasion traditionally excludes patients from transplant and ablation 4, SBRT has demonstrated safety and efficacy specifically for PVTT, even with main portal vein involvement 2, 5.

Multimodality Integration Strategy

Combination with TACE

The timing of TACE relative to radiotherapy is critical for survival benefit. Recent 2025 data identified combined TACE within one month post-RT as an independent favorable prognostic factor (HR 0.24, p=0.012) 2. This approach addresses the predominant failure pattern: 72.4% of progressions occur as outfield intrahepatic disease 2.

The rationale: TACE manages disease outside the radiation field while RT controls the PVTT, creating synergistic local-regional control.

Systemic Therapy Integration

Add TKI (sorafenib/lenvatinib) plus immunotherapy to the treatment regimen 7, 8. The 2025 comparative analysis showed that EBRT combined with TKI plus ICIs achieved median OS of 35 months versus 19 months with alternative approaches (p=0.044) 8. This combination is particularly effective for VP2-type PVTT (segmental/lobar branches), which applies to your segment-6 lesion scenario 8.

Technical Radiation Planning

For a segment-6 lesion with portal vein branch involvement:

• Target volume: Include both the parenchymal tumor and PVTT 2
• Median PTV: Approximately 105 cc (range 74-179 cc acceptable) 5
• Image guidance: MRI-guided real-time tumor tracking provides superior soft tissue visualization 2
• Location advantage: Segment 6 (posteroinferior right lobe) is generally favorable for SBRT as it's peripheral and away from central bile ducts 1

Expected Outcomes and Response Assessment

With optimal dosing (BED >75 Gy₁₀):

• Objective response rate: 45.8-61.7% 2, 6
• One-year local control: 77.7-93.3% 2, 3
• Median OS: 20-35 months with multimodality approach 5, 8
• Disease control at 3 months: 50% 7

Response to RT is itself a powerful prognostic factor (HR 0.33, p=0.026) 2, making early response assessment at 3 months critical for guiding subsequent management.

Safety Profile and Monitoring

Grade ≥3 toxicity rates are low (2.9%) with modern hypofractionated RT 5. However, monitor for:

• Leukopenia: More common with EBRT (46.2% grade 1-2) 8
• Liver enzyme elevation: Occurs in 38.5-70.7% (mostly grade 1-2) 8
• Decline in Child-Pugh score: Approximately one-third of patients experience ≥2 point decline within 3 months 7

Critical pitfall: Avoid TACE/TAE as monotherapy in macroscopic portal vein invasion, as occlusive hepatic artery embolization increases liver failure risk 4. However, TACE is safe and beneficial when combined with RT as described above.

Prognostic Factors to Guide Intensity

Independent predictors of better survival include:

• AFP <400 ng/mL (HR 0.329, p=0.013) 8
• Child-Pugh Class A (vs B/C: HR 2.30, p=0.02) 5
• Response to RT (HR 0.33, p=0.026) 2
• EBRT treatment (HR 2.247, p=0.030) 8

Use these factors to stratify treatment intensity and follow-up frequency.